South Africa: Phatisa exits vaccine manufacturer
Phatisa’s Food Fund 2 has agreed to sell its interest in Deltamune.
** For the best experience, download the free Africa Private Equity News app Android | iOS **
Phatisa’s Food Fund 2 has agreed to sell its interest in Deltamune, a South Africa-based vaccine manufacturer, to Vaxxinova International, a global animal health company and part of the EW Group.
Detailed transaction parameters were not disclosed.
Established in 1995, Deltamune develops and manufactures vaccines for production animals, with a focus on poultry and an expanding presence in the ruminant segment, including cattle and sheep.
The company produces nearly 15 million vaccine doses annually and supplies 12 countries across the SADC and COMESA regions.
Phatisa, together with management, acquired 100% of Deltamune from HL Hall & Sons in 2022. The management buyout and capital injection enabled Deltamune’s expansion across animal health verticals and into new markets.
Imane El Alaoui, partner at Phatisa said: “Our partnership with Deltamune embodies Phatisa’s commitment to backing innovation that delivers regional value and global relevance. This exit is more than a strong outcome – it is proof that local production capabilities, when scaled responsibly, can help Africa lead on food security, vaccine access, and pandemic resilience. We are proud to have accompanied Deltamune on this journey and we wish Deltamune and Vaxxinova the very best for the next chapter in the company’s history.”
Dr Stefan Swanepoel, managing director of Deltamune added: “Phatisa’s support enabled Deltamune to scale our reach, expand our product offering, and deepen our role in strengthening animal health across the region. With Vaxxinova, we will build on that foundation – advancing Africa’s ability to respond quickly and locally to both endemic and emerging animal health threats.”
Victor van Solinge, CEO of Vaxxinova said: “We are excited to welcome Deltamune to the Vaxxinova group. This is a perfect cultural, strategic and operational fit where all stakeholders in and outside South Africa will benefit. In sub-Saharan Africa, the combined companies will offer an enriched portfolio of products and services. The now extended Vaxxinova group and its customers will benefit from exchange of technologies and expertise. We are grateful to Phatisa for allowing us to acquire Deltamune.”
Stay ahead in Africa's private equity and venture capital sector with Africa Private Equity News’ monthly Dealmaker’s Log – a database of reported investment deals, exits, and fundraising closes. Subscribe here